From the subgroup analysis, it was observed that the cost-effectiveness of mepolizumab increases in specific subgroups, achieving an ICER of $46.640 USD in patients with eosinophils count of 300 and more cell/mcL and an exacerbation history of at least 4 exacerbations in the past year. Conclusions: In the light of the Chilean threshold, mepolizumab cannot be considered a cost-effective strategy. However, price discount in specific subgroups improves its cost-effectiveness profile significantly. It was estimated an ICER of $24.116 USD in the best performance subgroup with a 50% price discount.